Literature DB >> 21850406

CD30+ neoplasms of the skin.

Madeleine Duvic1.   

Abstract

Cutaneous T-cell lymphomas (CTCLs) are subdivided by lesion morphology, behavior, and surface receptors. Mycosis fungoides (MF) and Sézary syndrome (SS) are derived from CD4+ effector or central memory T-cells respectively. MF presents clinically as patches, plaques, or tumors, and SS presents with erythroderma. After MF/SS, the next most common CTCLs are CD30+ lymphoproliferative disorders: self-regressing lymphomatoid papulosis (LyP) or tumors of anaplastic large-cell lymphoma (ALCL), which express high levels of tumor necrosis factor death receptor member 8, also called CD30. Although MF is not considered to be a CD30+ lymphoproliferative disorder, MF may co-exist with LyP lesions, and MF may express CD30, especially in the setting of large-cell transformation. The development of targeted therapy for CD30+ CTCLs will help in understanding the importance of the CD30 death receptor in pathogenesis and will improve treatment options.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21850406     DOI: 10.1007/s11899-011-0096-8

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  30 in total

Review 1.  CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.

Authors:  H Stein; H D Foss; H Dürkop; T Marafioti; G Delsol; K Pulford; S Pileri; B Falini
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

Review 2.  Management of multifocal primary cutaneous CD30 anaplastic large cell lymphoma.

Authors:  James M Shehan; Amer N Kalaaji; Svetomir N Markovic; Iftikhar Ahmed
Journal:  J Am Acad Dermatol       Date:  2004-07       Impact factor: 11.527

3.  CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.

Authors:  Rakhshandra Talpur; Daniel M Jones; Alvaro J Alencar; Narin Apisarnthanarax; Kelly L Herne; Ying Yang; Madeleine Duvic
Journal:  J Invest Dermatol       Date:  2006-03       Impact factor: 8.551

4.  A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders.

Authors:  Madeleine Duvic; Sunil A Reddy; Lauren Pinter-Brown; Neil J Korman; John Zic; Dana A Kennedy; Jennie Lorenz; Eric L Sievers; Youn H Kim
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

5.  CD30 antigen in non-Hodgkin's lymphoma.

Authors:  K Miyake; T Yoshino; A B Sarker; N Teramoto; T Akagi
Journal:  Pathol Int       Date:  1994-06       Impact factor: 2.534

Review 6.  Primary cutaneous Ki-1(CD30) positive anaplastic large cell lymphoma in childhood.

Authors:  M M Tomaszewski; J C Moad; G P Lupton
Journal:  J Am Acad Dermatol       Date:  1999-05       Impact factor: 11.527

Review 7.  WHO-EORTC classification for cutaneous lymphomas.

Authors:  Rein Willemze; Elaine S Jaffe; Günter Burg; Lorenzo Cerroni; Emilio Berti; Steven H Swerdlow; Elisabeth Ralfkiaer; Sergio Chimenti; José L Diaz-Perez; Lyn M Duncan; Florent Grange; Nancy Lee Harris; Werner Kempf; Helmut Kerl; Michael Kurrer; Robert Knobler; Nicola Pimpinelli; Christian Sander; Marco Santucci; Wolfram Sterry; Maarten H Vermeer; Janine Wechsler; Sean Whittaker; Chris J L M Meijer
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

8.  A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases.

Authors:  Andrea Saggini; Andrea Gulia; Zsolt Argenyi; Regina Fink-Puches; Amelia Lissia; Mario Magaña; Luis Requena; Ingrid Simonitsch; Lorenzo Cerroni
Journal:  Am J Surg Pathol       Date:  2010-08       Impact factor: 6.394

9.  Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines.

Authors:  G Del Prete; M De Carli; F Almerigogna; C K Daniel; M M D'Elios; G Zancuoghi; F Vinante; G Pizzolo; S Romagnani
Journal:  FASEB J       Date:  1995-01       Impact factor: 5.191

10.  Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients.

Authors:  J H Kunishige; H McDonald; G Alvarez; M Johnson; V Prieto; M Duvic
Journal:  Clin Exp Dermatol       Date:  2009-01-16       Impact factor: 3.470

View more
  6 in total

Review 1.  CD30 expression in peripheral T-cell lymphomas.

Authors:  Elena Sabattini; Marco Pizzi; Valentina Tabanelli; Pamela Baldin; Carlo Sagramoso Sacchetti; Claudio Agostinelli; Pier Luigi Zinzani; Stefano A Pileri
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

Review 2.  Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.

Authors:  Lauren Shea; Neha Mehta-Shah
Journal:  Curr Hematol Malig Rep       Date:  2020-02       Impact factor: 3.952

3.  Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.

Authors:  Madeleine Duvic; Michael T Tetzlaff; Pamela Gangar; Audra L Clos; Dawen Sui; Rakhshandra Talpur
Journal:  J Clin Oncol       Date:  2015-08-10       Impact factor: 44.544

4.  Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results.

Authors:  Daniel J Lewis; Rakhshandra Talpur; Auris O Huen; Michael T Tetzlaff; Madeleine Duvic
Journal:  JAMA Dermatol       Date:  2017-12-01       Impact factor: 10.282

5.  Prognostic significance of CD30 expression in nasal natural killer/T-cell lymphoma.

Authors:  Guan-Nan Wang; Wu-Gan Zhao; Ling Li; Dan-Dan Zhang; Xian-Zheng Gao; Jun Zhou; Lei Zhang; Xiao-Rui Fu; Xiang-Yu Zheng; Ye Li; Zhen Li; Ming-Zhi Zhang; Wen-Cai Li
Journal:  Oncol Lett       Date:  2017-01-11       Impact factor: 2.967

Review 6.  Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL.

Authors:  Shaheer Khan; Ahmed Sawas
Journal:  Front Oncol       Date:  2019-07-30       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.